Literature DB >> 25617500

Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios.

Ingmar Wolffram1, David Petroff2, Olaf Bätz3, Katrin Jedrysiak3, Jan Kramer3, Hannelore Tenckhoff4, Thomas Berg4, Johannes Wiegand5.   

Abstract

BACKGROUND & AIMS: Prevalence data for hepatitis B and C and an evaluation of a guideline based screening in the primary care setting are not yet available. We therefore implemented a hepatitis B surface antigen (HBsAg) and anti-hepatitis C virus (HCV) screening and developed guideline based screening strategies.
METHODS: HBsAg, anti-HCV, and alanine aminotransferase (ALT) were included in a routine check-up together with a questionnaire covering 16 guideline adapted risk scenarios. Significant risk factors were identified by stepwise logistic regression.
RESULTS: 51 private practices screened 21,008 patients. The HBsAg, anti-HCV, and HCV-RNA prevalence was 0.52%, 0.95%, and 0.43%, respectively. Infections were previously unknown in 85% and 65% of HBsAg and anti-HCV positive individuals, respectively. Sexual risk factors were under-reported, while the following scenarios were significantly associated with viral infections (Odds ratio [95% confidence interval]). HBV: Immigration (4.4 [2.9, 6.7]), infection in household (2.5 [1.2, 4.5]), male gender (1.6 [1.1, 2.4]). Male immigrants had a 2.1% HBsAg prevalence and 80% were unaware of the infection. HCV: IV drug use (384 [233, 644]), blood transfusion before 1992 (5.3 [3.5, 7.9]), immigration (2.4 [1.5, 3.6]). Presence of either one of the HBV related guideline defined risk scenarios or elevated ALT identified 82% of previously undiagnosed patients. Presence of one of the three significant HCV risk factors or elevated ALT levels diagnosed 83% of unknown HCV-RNA positive cases by screening only 26% of the population.
CONCLUSIONS: Undiagnosed hepatitis B and C infections frequently exist in the primary care setting. Easy to apply guideline defined risk scenarios help to diagnose previously unknown infections.
Copyright © 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Efficacy; Hepatitis B; Hepatitis C; Screening strategy

Mesh:

Substances:

Year:  2015        PMID: 25617500     DOI: 10.1016/j.jhep.2015.01.011

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  21 in total

Review 1.  Regional Epidemiology, Burden, and Management of Hepatitis B Virus in the Middle East.

Authors:  Murat Akyıldız; Emel Ahıskalı; Müjdat Zeybel; Cihan Yurdaydın
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-01-29

Review 2.  The role of the general practitioner in the screening and clinical management of chronic viral hepatitis in six EU countries.

Authors:  A Bechini; M Levi; A Falla; A Ahmad; I Veldhuijzen; E Tiscione; P Bonanni
Journal:  J Prev Med Hyg       Date:  2016

3.  Hepatitis C - Assessment to Treatment Trial (HepCATT) in primary care: study protocol for a cluster randomised controlled trial.

Authors:  Kirsty Roberts; John Macleod; Chris Metcalfe; Joanne Simon; Jeremy Horwood; William Hollingworth; Sharon Marlowe; Fiona H Gordon; Peter Muir; Barbara Coleman; Peter Vickerman; Graham I Harrison; Cherry-Ann Waldron; William Irving; Matthew Hickman
Journal:  Trials       Date:  2016-07-29       Impact factor: 2.279

4.  Knowledge, Attitude, Behavior, and Practices Regarding HIV, Viral Hepatitis, and Sexually Transmitted Infections Among Migrants From Sub-Saharan Africa Living in Germany: A Multicenter Survey Protocol.

Authors:  Claudia Santos-Hövener; Carmen Koschollek; Anna Kuehne; Adama Thorlie; Viviane Bremer
Journal:  JMIR Res Protoc       Date:  2017-05-02

5.  Prevalence of hepatitis C virus in adult population in the Czech Republic - time for birth cohort screening.

Authors:  Roman Chlibek; Jan Smetana; Renata Sosovickova; Peter Gal; Petr Dite; Vlasta Stepanova; Lenka Pliskova; Stanislav Plisek
Journal:  PLoS One       Date:  2017-04-13       Impact factor: 3.240

6.  Economic study of the value of expanding HCV treatment capacity in Germany.

Authors:  Urbano Sbarigia; Daniel Wirth; Karen Van Nuys; Caroline Huber; Ron Brookmeyer; Jona Stahmeyer; Christian Krauth
Journal:  BMJ Open Gastroenterol       Date:  2017-04-04

7.  Language support for linguistic minority chronic hepatitis B/C patients: an exploratory study of availability and clinicians' perceptions of language barriers in six European countries.

Authors:  Abby M Falla; Irene K Veldhuijzen; Amena A Ahmad; Miriam Levi; Jan Hendrik Richardus
Journal:  BMC Health Serv Res       Date:  2017-02-20       Impact factor: 2.655

8.  Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: a focus on migrants from anti-HCV endemic countries.

Authors:  A M Falla; A A Ahmad; E Duffell; T Noori; I K Veldhuijzen
Journal:  BMC Infect Dis       Date:  2018-01-16       Impact factor: 3.090

9.  Limited access to hepatitis B/C treatment among vulnerable risk populations: an expert survey in six European countries.

Authors:  Abby M Falla; Irene K Veldhuijzen; Amena A Ahmad; Miriam Levi; Jan Hendrik Richardus
Journal:  Eur J Public Health       Date:  2017-04-01       Impact factor: 3.367

10.  Effect of a Cooperation Strategy between Primary Care Physicians and Hospital Liver Units on HBV Care in Campania, Italy.

Authors:  Rosa Zampino; Nicolina Capoluongo; Adriana Boemio; Margherita Macera; Martina Vitrone; Luigi Elio Adinolfi; Pietro Filippini; Evangelista Sagnelli; Caterina Sagnelli; Emanuele Durante-Mangoni; Nicola Coppola
Journal:  Can J Gastroenterol Hepatol       Date:  2018-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.